Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-14
2011-06-14
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S105000
Reexamination Certificate
active
07960377
ABSTRACT:
The invention provides compounds having the structure of formula I,and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R1, R2, R3and R4are defined in the specification. These compounds can be administered in pharmaceutical formulations to modulate cannabinoid receptor activity for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.
REFERENCES:
patent: 2007/0191603 (2007-08-01), Ackermann et al.
patent: WO03032989 (2003-04-01), None
patent: WO2004052373 (2006-12-01), None
patent: WO2006134378 (2006-12-01), None
patent: WO 2007093507 (2007-08-01), None
patent: WO2009120660 (2009-10-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Hanus, O.L.,Discovery and Isolation of Anandamide and Other Endocannabinoids, Chemistry and Biodiversity (2007), vol. 4: 1828-1841, Verlag Hely. Chim. Acta AG, Zurich.
Mackie, K.,Cannabinoid Receptors as Therapeutics Targets, Annu. Rev. Pharmacol. Toxicol. (2006) vol. 46: 101-122.
Pertwee, R.G.,The Therapeutic Potential of Drugs That Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids, AAPS Journal (2005) vol. 7(3) Article 64:E625-E654.
Raitio, K.H. et al.,Targeting the Cannabinoid CB2 Receptor: Mutations, Modeling and Development of CB2 Selective Ligands, Curr. Med. Chem. (2005) vol. 12:1217-1237.
Mackie K. and Ross, R.A.,CB2 cannabinoid receptors: new vistas, Br. J. Pharmacol. (2008) vol. 153:177-178.
Gustafson Gary R.
Newcom Jason S.
O'Connor Stephen J.
Algis Anilionis
Cara Therapeutics, Inc.
Habte Kahsay T
LandOfFree
Substituted pyridoxazines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyridoxazines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyridoxazines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712234